Evidence map›Paper›PMID 40110658›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

The impact of arteriolosclerosis on cognitive impairment in decedents without severe dementia from the National Alzheimer's Coordinating Center.

Cellas A Hayes, Christina B Young, Carla Abdelnour, Alexis Reeves, Michelle C Odden, Jeffrey Nirschl, Paul K Crane, Kathleen L Poston, Elizabeth C Mormino, Kyan Younes

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. MIND diet, cerebrovascular health, and cognition among community-dwelling older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
  5. STAT4-dependent regulation of neuroinflammation in atherosclerosis.bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. ARTS as a cardiometabolic biomarker to bridge gaps in dementia diagnostics and therapeutics.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  11. The cardiometabolic "bottleneck" on cognitive function in aging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  12. Targeting the cardiometabolic bottleneck to slow polypathology and cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cellas A HayesDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California, USA.ORCID 0000-0002-6259-9456
Christina B YoungDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Carla AbdelnourDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Alexis ReevesDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California, USA.
Michelle C OddenDepartment of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California, USA.
Jeffrey NirschlDepartment of Pathology, Stanford University, Stanford, California, USA.
Paul K CraneSchool of Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
Kathleen L PostonDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Elizabeth C MorminoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Kyan YounesDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.

Funding

National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
MVP Data Integration into the ADSP Phenotype Harmonization ConsortiumU24AG074855 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CUCCARO, MICHAEL L, HOHMAN, TIMOTHY J · 2021 to 2025
$37.5M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Teresa Gomez-Isla · 2019 to 2026
$36.5M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Mark W Bondi · 2019 to 2026
$34.9M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Barbara Brigitta Bendlin · 2019 to 2026
$34.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Carolyn Wei Zhu · 2020 to 2026
$31.0M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Miguel Arce · 2020 to 2026
$30.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
Alzheimer's Association AACSF-24-1307411Burroughs Wellcome Fund Postdoctoral Diversity Enrichment Program 1267001Iqbal Farrukh and Asad Jamal FundNIA NIH HHS K23 AG090733NIA NIH HHS P20 AG068024NIA NIH HHS P20 AG068053NIA NIH HHS P20 AG068077NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG079280NIA NIH HHS U24 AG072122NIA NIH HHS U24 AG074855NINDS NIH HHS 5R25NS124528NINDS NIH HHS R25 NS124528School of Medicine, Stanford University Propel Postdoctoral FellowshipSociety for Neuroscience Neuroscience Scholars Program
6 · The paper itself

Abstract

introductionAlzheimer's disease neuropathologic change (ADNC), Lewy body disease (LBD), and vascular neuropathologies occur together. Previous studies have been limited by a large majority of participants with severe dementia or advanced stages of pathologies, which limits the detectability of cognitive effects from vascular neuropathologies.

methodsUsing neuropathology data from the National Alzheimer's Coordinating Center, we examined the association of vascular neuropathologies with cognitive scores in participants without severe dementia (N = 1526) using multivariable linear regression.

resultsControlling for age, sex, education, LBD, and ADNC, arteriolosclerosis was associated with lower memory (β = -0.16 ± 0.06, p < 0.001), executive function (β = -0.25 ± 0.05, p < 0.001), and language scores (β = -0.20 ± 0.05, p < 0.001). The effects of arteriolosclerosis remained when controlling for vascular risk factors. DISCUSSION: Vascular neuropathologies exhibit distinct relationships with cognition. Arteriolosclerosis is an independent contributor to cognition. Further research should be conducted on whether arteriolosclerosis can serve as a surrogate marker for cognitive decline in early disease stages. HIGHLIGHTS: In individuals who do not have severe dementia, vascular neuropathologies are common, and the combination of pathologies is heterogeneous in a convenience sample from the Alzheimer's Disease Research Center that reported all the neuropathology data elements for this investigation. Arteriolosclerosis is associated with several cognitive domain scores, including memory, executive function, and language when controlling for the effects of Alzheimer's disease neuropathologic change and Lewy body disease. These results reinforce the importance of vascular pathology for cognition among people along the Alzheimer's disease spectrum.

Indexed as

Alzheimer DiseaseArteriolosclerosisCognitive DysfunctionAgedAged, 80 and overExecutive FunctionFemaleHumansLewy Body DiseaseMaleNeuropsychological TestsAlzheimer's pathologyarteriolosclerosiscognitionLewy body diseasemixed dementianeuropathologyvascular

Identifiers

PMID40110658
PMCPMC11923572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.